BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20949375)

  • 1. Tufted hair folliculitis in a woman treated with trastuzumab.
    Rosman IS; Anadkat MJ
    Target Oncol; 2010 Dec; 5(4):295-6. PubMed ID: 20949375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
    Ena P; Fadda GM; Ena L; Farris A; Santeufemia DA
    Clin Exp Dermatol; 2008 Nov; 33(6):790-1. PubMed ID: 18627387
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe folliculitis with secondary impetiginization in the scalp of a woman treated with panitumumab.
    Rodríguez Bandera AI; Gómez Fernández C; Vorlicka K; Ruiz-Bravo Burguillo E; Herranz Pinto P
    Int J Dermatol; 2015 Jun; 54(6):e226-9. PubMed ID: 25040914
    [No Abstract]   [Full Text] [Related]  

  • 5. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
    Garnock-Jones KP; Keating GM; Scott LJ
    BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
    [No Abstract]   [Full Text] [Related]  

  • 6. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
    Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
    J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of chemotherapy by anti-HER.
    Kataoka A; Ishida M; Murakami S; Ohno S
    Breast Cancer; 2004; 11(2):105-15. PubMed ID: 15550854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
    Lin A; Rugo HS
    Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR inhibitor-associated acneiform folliculitis: assessment and management.
    Duvic M
    Am J Clin Dermatol; 2008; 9(5):285-94. PubMed ID: 18717603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tykerb for breast cancer].
    Suzuki Y; Saito Y; Okamura T; Tokuda Y
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):892-5. PubMed ID: 21677477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
    Haq B; Geyer CE
    Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
    Kabe KL; Kolesar JM
    Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of trastuzumab.
    Jones RL; Smith IE
    Expert Opin Drug Saf; 2004 Jul; 3(4):317-27. PubMed ID: 15268649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer.
    Tham YL; Verani MS; Chang J
    Breast Cancer Res Treat; 2002 Jul; 74(2):131-4. PubMed ID: 12186373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
    Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
    Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.
    Karabay CY; Kocabay G; Kalayci A; Zehir R; Tanboga H
    Cardiology; 2010; 117(4):296-300. PubMed ID: 21358201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.